Which has preferable valuation & earnings, CBLL or INFU?

InfuSystem has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $89.06M 7.83 -$53.41M -$1.63 N/A InfuSystem $142.40M 1.29 $870K $0.38 23.89

Is CBLL or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to CeriBell's net margin of -63.51%. InfuSystem's return on equity of 2.78% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% InfuSystem 1.12% 2.78% 1.41%

Does the media favor SSII or INFU?

In the previous week, SS Innovations International had 1 more articles in the media than InfuSystem. MarketBeat recorded 2 mentions for SS Innovations International and 1 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.95 beat SS Innovations International's score of 0.73 indicating that InfuSystem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SS Innovations International 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive InfuSystem 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings and valuation, INFU or SIBN?

InfuSystem has higher earnings, but lower revenue than SiBone. SiBone is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $142.40M 1.29 $870K $0.38 23.89 SiBone $200.93M 3.52 -$18.90M -$0.39 N/A

Is INFU or SIBN more profitable?

InfuSystem has a net margin of 1.12% compared to SiBone's net margin of -8.10%. InfuSystem's return on equity of 2.78% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets InfuSystem 1.12% 2.78% 1.41% SiBone -8.10% -9.56% -7.06%

Does the media prefer INFU or SIBN?

In the previous week, InfuSystem and InfuSystem both had 1 articles in the media. InfuSystem's average media sentiment score of 1.95 beat SiBone's score of 0.00 indicating that InfuSystem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InfuSystem 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SiBone 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, INFU or BBNX?

InfuSystem has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $142.40M 1.29 $870K $0.38 23.89 Beta Bionics $110.24M 5.53 -$73.20M -$1.51 N/A

Is INFU or BBNX more profitable?

InfuSystem has a net margin of 1.12% compared to Beta Bionics' net margin of -60.27%. InfuSystem's return on equity of 2.78% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets InfuSystem 1.12% 2.78% 1.41% Beta Bionics -60.27% -23.00% -20.55%

Does the media prefer INFU or BBNX?

In the previous week, Beta Bionics had 4 more articles in the media than InfuSystem. MarketBeat recorded 5 mentions for Beta Bionics and 1 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.95 beat Beta Bionics' score of 1.06 indicating that InfuSystem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InfuSystem 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Beta Bionics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

InfuSystem (INFU) Competitors

$9.08 +0.16 (+1.79%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$9.08 0.00 (-0.01%)

As of 06/23/2026 06:35 PM Eastern

Compare

INFU vs. CBLL, SSII, SIBN, BBNX, and TCMD

Should you buy InfuSystem stock or one of its competitors? MarketBeat compares InfuSystem with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InfuSystem include CeriBell (CBLL), SS Innovations International (SSII), SiBone (SIBN), Beta Bionics (BBNX), and Tactile Systems Technology (TCMD). These companies are all part of the "medical equipment" industry.

How does InfuSystem compare to CeriBell?

CeriBell (NASDAQ:CBLL) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

InfuSystem has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.83	-$53.41M	-$1.63	N/A
InfuSystem	$142.40M	1.29	$870K	$0.38	23.89

71.1% of InfuSystem shares are owned by institutional investors. 20.1% of CeriBell shares are owned by insiders. Comparatively, 10.8% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CeriBell has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

In the previous week, InfuSystem had 1 more articles in the media than CeriBell. MarketBeat recorded 1 mentions for InfuSystem and 0 mentions for CeriBell. InfuSystem's average media sentiment score of 1.95 beat CeriBell's score of 0.00 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Overall Sentiment
CeriBell	Neutral
InfuSystem	Very Positive

CeriBell currently has a consensus target price of $22.20, indicating a potential upside of 20.72%. InfuSystem has a consensus target price of $15.00, indicating a potential upside of 65.20%. Given InfuSystem's higher possible upside, analysts plainly believe InfuSystem is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

InfuSystem has a net margin of 1.12% compared to CeriBell's net margin of -63.51%. InfuSystem's return on equity of 2.78% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
InfuSystem	1.12%	2.78%	1.41%

Summary

InfuSystem beats CeriBell on 12 of the 17 factors compared between the two stocks.

How does InfuSystem compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and InfuSystem (NYSE:INFU) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

InfuSystem has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$48.47M	14.04	-$12.13M	-$0.05	N/A
InfuSystem	$142.40M	1.29	$870K	$0.38	23.89

SS Innovations International presently has a consensus target price of $7.00, indicating a potential upside of 105.88%. InfuSystem has a consensus target price of $15.00, indicating a potential upside of 65.20%. Given SS Innovations International's higher possible upside, research analysts clearly believe SS Innovations International is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

71.1% of InfuSystem shares are held by institutional investors. 10.8% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, SS Innovations International had 1 more articles in the media than InfuSystem. MarketBeat recorded 2 mentions for SS Innovations International and 1 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.95 beat SS Innovations International's score of 0.73 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SS Innovations International	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
InfuSystem	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

InfuSystem has a net margin of 1.12% compared to SS Innovations International's net margin of -20.69%. InfuSystem's return on equity of 2.78% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
InfuSystem	1.12%	2.78%	1.41%

SS Innovations International has a beta of -1.89, suggesting that its stock price is 289% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

Summary

InfuSystem beats SS Innovations International on 13 of the 16 factors compared between the two stocks.

How does InfuSystem compare to SiBone?

InfuSystem (NYSE:INFU) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

InfuSystem has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, SiBone has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

In the previous week, InfuSystem and InfuSystem both had 1 articles in the media. InfuSystem's average media sentiment score of 1.95 beat SiBone's score of 0.00 indicating that InfuSystem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InfuSystem	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
SiBone	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InfuSystem has higher earnings, but lower revenue than SiBone. SiBone is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40M	1.29	$870K	$0.38	23.89
SiBone	$200.93M	3.52	-$18.90M	-$0.39	N/A

InfuSystem has a net margin of 1.12% compared to SiBone's net margin of -8.10%. InfuSystem's return on equity of 2.78% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
SiBone	-8.10%	-9.56%	-7.06%

InfuSystem presently has a consensus target price of $15.00, suggesting a potential upside of 65.20%. SiBone has a consensus target price of $23.00, suggesting a potential upside of 44.20%. Given InfuSystem's higher probable upside, research analysts plainly believe InfuSystem is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 10.8% of InfuSystem shares are held by company insiders. Comparatively, 3.9% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

InfuSystem beats SiBone on 10 of the 15 factors compared between the two stocks.

How does InfuSystem compare to Beta Bionics?

InfuSystem (NYSE:INFU) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

In the previous week, Beta Bionics had 4 more articles in the media than InfuSystem. MarketBeat recorded 5 mentions for Beta Bionics and 1 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.95 beat Beta Bionics' score of 1.06 indicating that InfuSystem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InfuSystem	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Beta Bionics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InfuSystem presently has a consensus target price of $15.00, indicating a potential upside of 65.20%. Beta Bionics has a consensus target price of $19.70, indicating a potential upside of 44.11%. Given InfuSystem's stronger consensus rating and higher probable upside, research analysts clearly believe InfuSystem is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

InfuSystem has a net margin of 1.12% compared to Beta Bionics' net margin of -60.27%. InfuSystem's return on equity of 2.78% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Beta Bionics	-60.27%	-23.00%	-20.55%

71.1% of InfuSystem shares are held by institutional investors. 10.8% of InfuSystem shares are held by insiders. Comparatively, 5.3% of Beta Bionics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

InfuSystem has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40M	1.29	$870K	$0.38	23.89
Beta Bionics	$110.24M	5.53	-$73.20M	-$1.51	N/A

InfuSystem has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.4, meaning that its share price is 240% more volatile than the broader market.

Summary

InfuSystem beats Beta Bionics on 12 of the 17 factors compared between the two stocks.

How does InfuSystem compare to Tactile Systems Technology?

InfuSystem (NYSE:INFU) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

In the previous week, InfuSystem had 1 more articles in the media than Tactile Systems Technology. MarketBeat recorded 1 mentions for InfuSystem and 0 mentions for Tactile Systems Technology. InfuSystem's average media sentiment score of 1.95 beat Tactile Systems Technology's score of 0.00 indicating that InfuSystem is being referred to more favorably in the media.

Company	Overall Sentiment
InfuSystem	Very Positive
Tactile Systems Technology	Neutral

InfuSystem currently has a consensus price target of $15.00, indicating a potential upside of 65.20%. Tactile Systems Technology has a consensus price target of $38.60, indicating a potential upside of 45.94%. Given InfuSystem's higher probable upside, equities analysts plainly believe InfuSystem is more favorable than Tactile Systems Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Tactile Systems Technology has a net margin of 5.91% compared to InfuSystem's net margin of 1.12%. Tactile Systems Technology's return on equity of 9.70% beat InfuSystem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Tactile Systems Technology	5.91%	9.70%	7.53%

Tactile Systems Technology has higher revenue and earnings than InfuSystem. InfuSystem is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40M	1.29	$870K	$0.38	23.89
Tactile Systems Technology	$329.52M	1.81	$19.09M	$0.88	30.06

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are held by institutional investors. 10.8% of InfuSystem shares are held by insiders. Comparatively, 2.1% of Tactile Systems Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

InfuSystem has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Tactile Systems Technology has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Summary

Tactile Systems Technology beats InfuSystem on 11 of the 17 factors compared between the two stocks.

Get InfuSystem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INFU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INFU vs. The Competition

Export

Metric	InfuSystem	Surgical & medical instruments Industry	Medical Sector	NYSE Exchange
Market Cap	$180.02M	$41.13M	$6.44B	$23.25B
Dividend Yield	N/A	1.08%	2.69%	4.07%
P/E Ratio	151.36	17.72	24.67	31.08
Price / Sales	1.29	27.83	528.41	105.78
Price / Cash	12.79	18.86	44.82	24.45
Price / Book	3.68	8.22	10.76	4.64
Net Income	$870K	-$20.39M	$3.56B	$1.07B
7 Day Performance	3.77%	-3.12%	1.03%	0.15%
1 Month Performance	-6.00%	-10.04%	0.45%	0.18%
1 Year Performance	45.05%	-13.40%	29.69%	23.21%

InfuSystem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INFU InfuSystem	4.4246 of 5 stars	$9.08 +1.8%	$15.00 +65.2%	+46.9%	$180.02M	$142.40M	151.36	410	News Coverage Positive News
CBLL CeriBell	2.3741 of 5 stars	$17.92 -3.6%	$22.20 +23.9%	-0.5%	$705.36M	$95.07M	N/A	N/A
SSII SS Innovations International	2.7082 of 5 stars	$3.47 -1.4%	$7.00 +101.7%	-39.8%	$704.46M	$42.49M	N/A	4	Gap Down
SIBN SiBone	1.7848 of 5 stars	$15.41 +1.9%	$23.00 +49.3%	-3.5%	$670.56M	$200.93M	N/A	350
BBNX Beta Bionics	3.5454 of 5 stars	$13.95 -3.0%	$19.70 +41.2%	-13.5%	$640.80M	$100.25M	N/A	294	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:INFU) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InfuSystem (INFU) Competitors

INFU vs. CBLL, SSII, SIBN, BBNX, and TCMD

How does InfuSystem compare to CeriBell?

Summary

How does InfuSystem compare to SS Innovations International?

Summary

How does InfuSystem compare to SiBone?

Summary

How does InfuSystem compare to Beta Bionics?

Summary

How does InfuSystem compare to Tactile Systems Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InfuSystem (INFU) Competitors

INFU vs. CBLL, SSII, SIBN, BBNX, and TCMD

How does InfuSystem compare to CeriBell?

Which has preferable valuation & earnings, CBLL or INFU?

Do insiders & institutionals have more ownership in CBLL or INFU?

Which has more risk & volatility, CBLL or INFU?

Does the media refer more to CBLL or INFU?

Do analysts recommend CBLL or INFU?

Is CBLL or INFU more profitable?

Summary

How does InfuSystem compare to SS Innovations International?

Which has better valuation & earnings, SSII or INFU?

Do analysts recommend SSII or INFU?

Do institutionals & insiders believe in SSII or INFU?

Does the media favor SSII or INFU?

Is SSII or INFU more profitable?

Which has more risk and volatility, SSII or INFU?

Summary

How does InfuSystem compare to SiBone?

Which has more risk & volatility, INFU or SIBN?

Does the media prefer INFU or SIBN?

Which has higher earnings and valuation, INFU or SIBN?

Is INFU or SIBN more profitable?

Do analysts rate INFU or SIBN?

Do insiders & institutionals hold more shares of INFU or SIBN?

Summary

How does InfuSystem compare to Beta Bionics?

Does the media prefer INFU or BBNX?

Do analysts prefer INFU or BBNX?

Is INFU or BBNX more profitable?

Do institutionals & insiders have more ownership in INFU or BBNX?

Which has preferable valuation and earnings, INFU or BBNX?

Which has more risk & volatility, INFU or BBNX?

Summary

How does InfuSystem compare to Tactile Systems Technology?

Does the media favor INFU or TCMD?

Do analysts recommend INFU or TCMD?

Is INFU or TCMD more profitable?

Which has higher valuation & earnings, INFU or TCMD?

Do institutionals and insiders hold more shares of INFU or TCMD?

Which has more risk & volatility, INFU or TCMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools